Composition for immediate and extended release
AssigneeFerring B.V.
InventorsVarinder Ahuja, Rajan Verma, Umesh Vinayakrao Barabde, Arne Hagsten, Kristin Wannerberger, Rambabu Boorugu, Amol Vilasrao Somwanshi
Life of this patent
Estimating the term…
Abstract
The subject invention relates to fast dissolving pharmaceutical compositions comprising an active ingredient for immediate release and further comprising a controlled release dosage form comprising an active ingredient for controlled release.
Claims40
A pharmaceutical composition comprising
- an open matrix network comprising a first pharmaceutically active ingredient;
- one or more matrix-forming agents;
- and
- controlled release beads comprising a second pharmaceutically active ingredient.
(canceled)
(canceled)
A process for preparing a pharmaceutical composition comprising sublimating a solvent from a liquid preparation comprising a first pharmaceutically active ingredient, one or more matrix-forming agents, controlled released pellets comprising a second pharmaceutically active ingredient, and a solvent.
A process for preparation of a pharmaceutical composition comprising the steps of:
- (a) preparing a mixture comprising a first active ingredient, controlled release beads comprising a second active ingredient, one or more matrix-forming agents, and a solvent;
- (b) freezing the mixture;
- and
- (c) sublimating the solvent from the frozen mixture,
- wherein the pharmaceutical composition so obtained disintegrates within 30 seconds upon contact with a standardized aqueous medium.
A method for treating overactive bladder, nocturia or a combination thereof in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
- an open matrix network comprising a first pharmaceutical active ingredient;
- one or more matrix-forming agents;
- and controlled release beads comprising a second pharmaceutical active ingredient of an antimuscarinic compound.
A method for treating benign prostatic hyperplasia in a subject in need thereof, which comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising:
- an open matrix network comprising a first pharmaceutical active ingredient;
- one or more matrix-forming agents;
- and controlled release beads comprising a second pharmaceutical active ingredient of a selective alpha-blocker.
Dependencies are inferred from the claim text.